157 related articles for article (PubMed ID: 25702159)
21. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
23. CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity.
Jie J; Zhang Y; Zhou H; Zhai X; Zhang N; Yuan H; Ni W; Tai G
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558459
[TBL] [Abstract][Full Text] [Related]
24. Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy.
Madsen CB; Wandall HH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Dec; 35(6):649-52. PubMed ID: 24063621
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Miles DW; Taylor-Papadimitriou J
Pharmacol Ther; 1999 Apr; 82(1):97-106. PubMed ID: 10341360
[TBL] [Abstract][Full Text] [Related]
26. Intramolecular antigenicity of MUC1, a candidate for cancer vaccines.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(2):315-6. PubMed ID: 17696754
[TBL] [Abstract][Full Text] [Related]
27. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
28. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
29. Strategies used for MUC1 immunotherapy: human clinical studies.
Tang CK; Katsara M; Apostolopoulos V
Expert Rev Vaccines; 2008 Sep; 7(7):963-75. PubMed ID: 18767946
[TBL] [Abstract][Full Text] [Related]
30. MUC1 antibody-based therapeutics: the promise of cancer immunotherapy.
Pourjafar M; Samadi P; Saidijam M
Immunotherapy; 2020 Dec; 12(17):1269-1286. PubMed ID: 33019839
[TBL] [Abstract][Full Text] [Related]
31. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
Masaki Y; Oka M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model.
Gao FS; Zhan YT; Wang XD; Zhang C
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
Glaffig M; Stergiou N; Schmitt E; Kunz H
ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
[TBL] [Abstract][Full Text] [Related]
34. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.
Picco G; Beatson R; Taylor-Papadimitriou J; Burchell JM
Eur J Immunol; 2014 Jul; 44(7):1947-55. PubMed ID: 24648154
[TBL] [Abstract][Full Text] [Related]
35. Microvesicle cargo of tumor-associated MUC1 to dendritic cells allows cross-presentation and specific carbohydrate processing.
Rughetti A; Rahimi H; Belleudi F; Napoletano C; Battisti F; Zizzari IG; Antonilli M; Bellati F; Wandall HH; Benedetti Panici P; Burchell JM; Torrisi MR; Nuti M
Cancer Immunol Res; 2014 Feb; 2(2):177-86. PubMed ID: 24778281
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
37. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
38. A review on development of MUC1-based cancer vaccine.
Gao T; Cen Q; Lei H
Biomed Pharmacother; 2020 Dec; 132():110888. PubMed ID: 33113416
[TBL] [Abstract][Full Text] [Related]
39. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
[TBL] [Abstract][Full Text] [Related]
40. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
